Am­gen posts up­beat as­sess­ment of PhII KRAS da­ta on AMG510 — but there's no clear pic­ture of what re­searchers saw

It’s not un­usu­al to be left want­i­ng af­ter read­ing a top-line press re­lease on close­ly-watched tri­al da­ta. But Am­gen is tak­ing it to a whole new lev­el with its Phase II snap­shot on the KRAS G12c drug so­tora­sib — aka AMG 510.

The drug’s one sol­id shot at break­through sta­tus is in lung can­cer, where re­searchers found ev­i­dence of ef­fi­ca­cy in ear­ly-stage work. Now, they’re up to Phase II da­ta, which ex­ecs ear­li­er main­tained could pave the way to a quick OK, and the team is giv­ing lit­tle away.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN